Quest Diagnostics
About: Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Employees: 48,000
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
131% more call options, than puts
Call options by funds: $92.2M | Put options by funds: $39.9M
100% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 4 (+2) [Q2]
32% more first-time investments, than exits
New positions opened: 91 | Existing positions closed: 69
3% more funds holding
Funds holding: 799 [Q1] → 821 (+22) [Q2]
0% more capital invested
Capital invested by funds: $13.2B [Q1] → $13.3B (+$43.2M) [Q2]
7% less repeat investments, than reductions
Existing positions increased: 271 | Existing positions reduced: 292
2.64% less ownership
Funds ownership: 90.02% [Q1] → 87.38% (-2.64%) [Q2]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
Truist Securities David Macdonald 77% 1-year accuracy 33 / 43 met price target | 11%upside $165 | Hold Maintained | 7 Oct 2024 |
Evercore ISI Group Elizabeth Anderson 40% 1-year accuracy 10 / 25 met price target | 11%upside $165 | In-Line Reinstated | 28 Aug 2024 |
Barclays Stephanie Davis 78% 1-year accuracy 7 / 9 met price target | 3%upside $154 | Equal-Weight Maintained | 27 Aug 2024 |
Piper Sandler David Westenberg 73% 1-year accuracy 16 / 22 met price target | 1%upside $150 | Neutral Maintained | 29 Jul 2024 |
Baird Eric Coldwell 37% 1-year accuracy 7 / 19 met price target | 3%upside $154 | Neutral Maintained | 24 Jul 2024 |
Financial journalist opinion
Based on 13 articles about DGX published over the past 30 days